Skip to main content

Table 2 Parameters for all patients before and after TCZ treatment

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

  Before treatment After 3M treatment After 6M treatment
All patients All patients All patients
  Mean ± SD (range) Mean ± SD (range) Mean ± SD (range)
DAS28 4.7±1.4 (2.5-8.9) 3.2±1.5 (1.3-6.3)* 3.1±1.6 (0.9-6.7)*
DAS28-CRP 3.2±1.4 (1.3-8.9) 2.4±1.3 (1.0-5.2)* 2.4±1.4 (1.0-5.2)*
SDAI 20.2±16.6 (3.2-75.1) 10.4±10.8 (0.7-40.9)* 11.7±13.3 (0.1-42.8)*
CDAI 18.1±15.4 (2.8-68) 9.8±10.0 (0.7-39)* 11.1±13.0 (0.1-42.8)*
ESR (mm/h) 67.8±33.9 (14–122) 23.4±26.0 (3–107)* 20.9±25.0 (2–98)*
CRP (mg/dl) 2.16±2.72 (0.11-7.10) 0.60±1.48 (0.01-5.73)* 0.53±1.55 (0.00-6.25)*
MMP-3 (ng/ml) 302.6±254.2 (28.4-792.6) 150.1±153.4 (32.1-600.7)* 139.6±152.3 (10.0-545.4)*
Tender joints count 3.6±5.9 (0–24) 2.5±3.6 (0–13) 2.9±5.0 (0–18)
Swollen joints count 5.7±5.8 (0–24) 3.1±3.6 (0–15)* 3.8±4.9 (0–15)
P-VAS 39.9±29.0 (0–100) 22.5±24.1 (0–70)* 23.0±24.1 (0–71)*
E-VAS 47.9±26.9 (0–100) 19.4±15.9 (0–55)* 20.5±21.8 (1–77)*
  1. The data are presented as the mean (S.D.) (range). The average for each parameter was calculated before treatment and at follow-up.
  2. *indicates a significant difference compared with the value observed at baseline (p < 0.05). P-VAS: patient global disease activity represented by the visual analog scale. E-VAS: evaluator global disease activity represented by the visual analog scale.